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The KRAB-type zinc-ﬁnger protein Apak (ATM and p53 associated KZNF protein) speciﬁcally sup-
presses p53-mediated apoptosis. Upon DNA damage, Apak is phosphorylated and inhibited by
ATM kinase, resulting in p53 activation. However, how Apak is regulated in response to oncogenic
stress remains unknown. Here we show that upon oncogene activation, Apak is inhibited in the
tumor suppressor ARF-dependent but ATM-independent manner. Oncogene-induced ARF protein
directly interacts with Apak and competes with p53 to bind to Apak, resulting in Apak dissociation
from p53. Thus, Apak is differentially regulated in the ARF and ATM-dependent manner in response
to oncogenic stress and DNA damage, respectively.
Structured summary:
MINT-7989670: p53 (uniprotkb:P04637) binds (MI:0407) to APAK (uniprotkb:Q8TAQ5) by pull down
(MI:0096)
MINT-7989812:HDM2 (uniprotkb:Q00987) physically interacts (MI:0915) with ARF (uniprotkb:Q8N726-1)
by anti bait coimmunoprecipitation (MI:0006)
MINT-7989603, MINT-7989626: APAK (uniprotkb:Q8TAQ5) physically interacts (MI:0915) with ARF (uni-
protkb:Q8N726-1) by anti bait coimmunoprecipitation (MI:0006)
MINT-7989653: ARF (uniprotkb:Q8N726-1) binds (MI:0407) to APAK (uniprotkb:Q8TAQ5) by pull down
(MI:0096)
MINT-7989686, MINT-7989705, MINT-7989747: APAK (uniprotkb:Q8TAQ5) physically interacts (MI:0915)
with ARF (uniprotkb:Q8N726-1) by anti tag coimmunoprecipitation (MI:0007)
MINT-7989724: APAK (uniprotkb:Q8TAQ5) physically interacts (MI:0914) with ARF (uniprotkb:Q8N726-1)
and p53 (uniprotkb:P04637) by anti tag coimmunoprecipitation (MI:0007)
MINT-7989635: ARF (uniprotkb:Q8N726-1) and APAK (uniprotkb:Q8TAQ5) colocalize (MI:0403) by ﬂuo-
rescence microscopy (MI:0416)
MINT-7989584, MINT-7989773: APAK (uniprotkb:Q8TAQ5) physically interacts (MI:0915) with p53 (uni-
protkb:P04637) by anti tag coimmunoprecipitation (MI:0007)
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The p53 tumor suppressor protein acts as a major defense
against cancer. Loss of p53 function occurs during the development
of most, if not all, tumor types [1]. p53 functions as a node for inte-
grating whether the cell responds to various types and extents of
stress with apoptosis, cell cycle arrest, senescence, DNA repair, cellchemical Societies. Published by Emetabolism, or autophagy [2]. Although the basal level of p53 is
low in unstressed cells, p53 can be accumulated and activated in
response to a variety of cellular stresses, such as DNA damage,
oncogene activation, hypoxia and oxidative stress [3]. The p53
pathway is sensitive to DNA double-strand breaks or single-
stranded gaps in the early stage of tumorigenesis. Kinases includ-
ing ATM (ataxia-telangiectasia mutated) play a crucial part in the
immediate response to double-strand breaks through phosphory-
lation on p53 directly [1]. In response to oncogene activation,
p53 is induced through the ARF (alterative reading frame) tumorlsevier B.V. All rights reserved.
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largely independent of the ATM-mediated DNA damage pathway.
The mammalian p14ARF-p16INK4a locus (p19Arf in the mouse)
is frequently mutated in human cancers at an overall frequency of
approximately 40% [6–8]. ARF and p16 exist in alternate reading
frames with respect to the shared exon 2, and activate the p53
and the Rb tumor suppression pathways, respectively. Mice lacking
ARF (homozygous deletion of exon 1b) are prone to tumor
development [9], indicating the role of ARF in tumor suppression.
Endogenous ARF expression is elevated by oncogenic MYC, Ras,
E2F1, E1A and v-Abl, all of which activate p53-mediated cell cycle
arrest or apoptosis [10–15].
A few binding partners of p53 have been demonstrated to coor-
dinate the selective regulation of p53 target genes and direct a spe-
ciﬁc cellular outcome [3]. ASPPs, hCAS/CSE1L, Brn3b, Muc1 and
NFjB/p52 selectively activate the expression of apoptotic regula-
tors to promote cell death, whereas Brn3a, Hzf, and YB1 selectively
induce p53 activation of genes encoding cell cycle regulators to
facilitate cell cycle arrest. We previously identiﬁed the KRAB-type
zinc-ﬁnger (KZNF) protein Apak (ATM and p53 associated KZNF
protein) speciﬁcally inhibits p53-mediated apoptosis but has no
signiﬁcant effect on the transcription of cell cycle arrest-related
genes [16]. Apak interacts directly with p53 through its zinc-ﬁn-
gers and recruits KRAB-box-associated protein-1 (KAP-1) and his-
tone deacetylase 1 (HDAC1) to attenuate the acetylation of p53
through its N-terminal KRAB domain. The inhibitory function of
Apak requires the cooperation of ATM kinase. Notably, Apak is re-
quired for KAP-1 and ATM regulation of pro-apoptotic but not pro-
arrest p53 target genes [16], indicating that the Apak-containing
multi-component protein complex might be crucial in determining
the p53-mediated cell death. In response to DNA damage, MDM2,
p53 and Apak-KAP-1 complex could be sequentially phosphory-
lated by ATM [17–19]. The Apak phosphorylation on Ser68 by
ATM was a late event and caused the dissociation of Apak from
p53, allowing efﬁcient p53 activation followed by apoptosis to oc-
cur [16,20]. However, whether and how Apak is regulated in re-
sponse to oncogene activation remains unknown.
In this study, we utilized ectopic expression of c-MYC, E2F1 and
Ras-G12V mutant to mimic oncogene activation and investigated
the possible regulation of Apak function and the underlying mech-
anisms. We showed that Apak dissociates from p53 in an ARF-
dependent but ATM-independent manner through competitive
binding by ARF to Apak. Therefore, these ﬁndings deepen our
understandings of how the selective p53 regulator Apak was
regulated.2. Materials and methods
2.1. Plasmid constructs and antibodies
Plasmids containing human Apak and p53 were constructed by
PCR and recombinant PCR as described previously [16]. Human
ARF and a series of deletion mutants were constructed into the
EcoRI and XhoI sites of pCMV-Myc and pCMV-HA vectors (Clon-
tech). For subcellular localization analysis, ARF was subcloned into
the XhoI and BamHI sites of pDsRed1-N1 vector (Clontech) to ex-
press red ﬂuorescence protein (RFP)-tagged fusion protein. Wild-
type and mutant c-MYC, E2F1 plasmids are kind gifts from Dr.
Pingkun Zhou. Ras-V12 is a kind gift from Dr. Xuemin Zhang.
pCMV/HDM2 plasmid was a kind gift from Dr. Yue Xiong and de-
scribed previously [21]. Speciﬁc rabbit polyclonal antibodies recog-
nizing the Ser68-phosphorylated Apak or the unphosphorylated
Apak were prepared in our laboratory and described previously
[16]. Other antibodies used were anti-ARF (Oncogene), anti-Myc
(Clontech), Myc-HRP (Sigma), anti-Flag and anti-Flag-HRP (Sigma),anti-HA (Roche), anti-p53 (Oncogene), anti-p53-HRP (R&D sys-
tems), anti-Bax (Santa Cruz), anti-Noxa (Abnova), anti-Fas (Santa
Cruz) and anti-HDM2 (Santa Cruz).
2.2. Transfections, cell culture and MMS treatment
HCT116 human colon cancer cells (p53-wild type) were a kind
gift from Dr. Qimin Zhan and cultured in DMEM containing 10%
FBS. Human lung adenocarcinoma H1299 cells were maintained
in RPMI 1640 medium (Hyclone) with 10% FBS. Human embryonic
lung HEL cells were a kind gift from Dr. Yi Tie and cultured in
DMEM containing 10% FBS. Mammalian cells were transfected
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. Methyl methanesulfonate (MMS) was pur-
chased from Sigma and incubated with the cells for 4 h at the
concentration of 0.02%.
2.3. Luciferase reporter gene assay
The luciferase reporter plasmid pG13-Luc (pG13L containing 13
tandem p53 binding site repeats) was a kind gift of Dr. Bert Vogel-
stein. The luciferase reporter assaywas performed as described pre-
viously [16]. After 48 h transfection, cells were lysed in a passive
lysis buffer (Promega). The ﬁreﬂy and renilla luciferase activities
were measured with the Dual Luciferase Assay System (Promega)
and normalized according to the manufacturer’s protocol.
2.4. Immunoprecipitation, immunoblotting, and GST pull-down assays
At 24 h after transfection, cells were treated with the drug for
the indicated times and then harvested and lysed in HEPES lysis
buffer (20 mM HEPES pH 7.2, 50 mM NaCl, 0.5% Triton X-100,
1 mM NaF, 1 mM dithiothreitol) supplemented with protease
inhibitor cocktail (Roche). Immunoprecipitation and immunoblot-
ting, in vitro GST pull-down assays, were performed as we previ-
ously described [16,22].
2.5. Cell apoptosis and subcellular localization analysis
Apoptosis assay was performed with Annexin V staining meth-
od followed by ﬂow cytometry analysis as described [16]. For sub-
cellular localization analysis, GFP-Apak and RFP-ARF plasmids
were transfected into the H1299 cells. Thirty-six hours later, the
subcellular localization of Apak and ARF proteins were visualized
via a confocal microscope.
2.6. RNA interference
The Apak shRNA sequence (50-GGGATTATTTGGAAGCCAA-30)
and the control sequence (50-TGCGTTGCTAGTACCAAC-30, non-tar-
geting sequence) were cloned into RNAi-Ready pSIREN-DNRDs
Red-Express (Clontech) as described [16]. The ARF siRNA (50-
CUCGUGCUGAUGCUACUGA-30), ATR siRNA (50-AAGCGCCUGAUUC-
GAGAUCCU-30) and non-targeting control siRNA (50-UUCUCC
GAACGUGUCACGU-30) were synthesised by Shanghai GenePharm.
All siRNA transfections were performed with Lipofectamine 2000
(Invitrogen), and the interference efﬁciency was assessed by wes-
tern blot.
3. Results and discussion
3.1. Apak dissociates from p53 upon oncogene activation
independently of Apak phosphorylation
Since p53 lies at the node of signaling in response to diverse cel-
lular stresses including oncogenic stress and DNA damage, we
Fig. 1. Apak is negatively regulation upon oncogene activation independent of its phosphorylation. (A) p53-deﬁcient H1299 cells seeded in 24-well plate were transfected
with (black) or without (white) Myc-tagged Apak (0.4 lg) in combination with pG13L (0.2 lg), Flag-p53 (30 ng), HA-c-MYC (0.2 lg), HA-E2F1 (0.2 lg), Myc-Ras-V12 (0.2 lg)
and control luciferase RL-CMV (1 ng) as indicated. Thirty-six hours after transfection, the luciferase activity was measured and normalized. Representative results of three
independent reporter assay experiments are shown. Data are mean ± S.D. (standard deviation, n = 3). Western blot analysis of Apak, ARF and oncogene expression was also
shown. The antibodies used were indicated on the left and the detected proteins were indicated on the right. IB, immunoblotting. (B) H1299 cells were transfected with or
without shRNA-Apak (0.4 lg) in combination with pG13L, Flag-p53, HA-c-MYC, HA-E2F1, Myc-Ras-V12 similar to (A). Thirty-six hours after transfection, the luciferase
activity was measured and normalized. Representative results of three independent reporter assay experiments are shown. Western blot analysis of Apak, ARF and oncogene
expression was also shown. (C) H1299 cells seeded in 12-well plate were transfected with Myc-Apak (0.6 lg), Flag-p53 (0.4 lg) together with the indicated oncogenes
(0.4 lg). Expression of ectopic oncogenes, Apak, p53, and endogenous p53 target genes (Bax, Fas, Noxa) was analyzed by western blotting with the indicated antibodies. (D)
H1299 cells in 12-well plate were transfected with Myc-Apak, Flag-p53 together with the Myc-Ras-G12 V as in (C). At 36 h after transfection, cells were collected and
analyzed Apoptosis in H1299 cells was determined by staining with Annexin V. Data are mean ± S.D. (n = 3).(E) H1299 cells in 25 cm2 ﬂask were transfected with Myc-Apak
(4 lg), Flag-p53 (2 lg) together with the indicated oncogenes (2 lg) or treated with MMS (0.02% for 4 h). The cell lysates were immunoprecipitated with anti-Myc antibody.
Both the immunoprecipitate (IP) and the whole cell lysate (WCL) were analyzed by western blot with Myc and Flag antibodies. To avoid the interference of IgG heavy chain,
Flag-HRP antibody was used to analysis p53 in IP samples. IgG HC, heavy chain of IgG. (F) H1299 cells in 12-well plate were transfected with Myc-Apak (0.6 lg) and the
oncogenes (0.4 lg) as indicated. At 36 h post transfection, cell lysates were analyzed by western blot. MMS treatment was designed as a positive control to indicate the
phosphorylation of Apak. (G) Interaction between Myc-Apak-S68A and p53 was abolished by oncogene activation, but not by MMS treatment. H1299 cells were transfected
with Apak-S68A and the indicated plasmids. Co-immunoprecipitation assays were performed as in (E).
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oncogenic stress mimicked by ectopic expression of c-MYC, E2F1 or
Ras-V12, and if it is the case, what is the mechanism. Overexpres-
sion of Apak resulted in the remarkable decrease of p53 transcrip-
tional activity (Fig. 1A, column 2 v.s. column 1) whereas
overexpression of the c-MYC, E2F1 or Ras-V12 upregulated ARF
expression and p53 activity as expected (columns 3, 5 and 7). In
these stressed cells, Apak no longer inhibited p53 activity signiﬁ-
cantly (columns 4, 6, 8 v.s. columns 3, 5, 7, respectively). Depletion
of endogenous Apak resulted in an increase of p53 transcriptional
activity in the absence of stress whereas it had no signiﬁcant effect
on p53 activity in the presence of oncogenic stress (Fig. 1B).
Expression analysis of p53 pro-apoptotic target genes showed that
oncogenic stress reversed the inhibitory effects of Apak on p53
transcriptional activation (Fig. 1C). Apak inhibited the p53-induced
cell apoptosis (Fig. 1D, column 4 v.s. column 3) and Ras-V12 ecto-
pic expression signiﬁcantly reversed the effect of Apak (column 5
v.s. column 4). These results indicated that Apak was functionally
inhibited in response to oncogene activation.
Co-immunoprecipitation assays showed that like the treatment
with DNA damaging agent methyl methanesulfonate (MMS),
expression of c-MYC, E2F1 or Ras-V12 induced Apak dissociation
from p53 (Fig. 1E). We previously demonstrated that MMS treat-
ment triggers Apak phosphorylation on Ser68 by ATM kinase and
this phosphorylation is both sufﬁcient and necessary for DNA dam-
age-induced Apak-p53 dissociation [16,20]. We then ask whether
the dissociation of Apak from p53 in response to oncogenic stress
is similar to or distinct from the case in response to DNA damage
stress. Direct western blot analysis with the anti-phospho-Apak-
Ser68 antibody did not detected any band in c-MYC, E2F1 and
Ras-V12-expressing cells, although the total Apak protein level
was upregulated compared with the unstressed cells (Fig. 1F, lanes
3-5). As a positive control, Apak phosphorylation could be easily
detected in MMS-treated cells (lane 1). Substitution of Ser68 with
alanine had no effect on the dissociation of Apak from p53 in
response to oncogene activation but blocked their dissociation in
response to MMS treatment (Fig. 1G). These data suggested that
the negative regulation of Apak activity in response to oncogene
activation was independent on Apak phosphorylation, at least the
ATM kinase-mediated phosphorylation on Ser68.
3.2. Apak is negatively regulated dependently of ARF upon oncogene
activation
It has been well-accepted that in response to oncogene activa-
tion, p53 is induced and activated largely through the ARF tumor
suppressor pathway [4,5]. We then examined whether the nega-
tive regulation of Apak function is dependent on ARF. Knockdown
of endogenous ARF by RNA interference (RNAi) but not control
small interfering RNA (siRNA) transfection blocked the negative
regulation of Apak activity by oncogene activation (Fig. 2A). ARF
knockdown also prevented the oncogene-induced dissociation be-
tween Apak and p53 and then inhibited p53 accumulation
(Fig. 2B). Similar results were obtained in H1299 cancer cells
(Fig. 2A and B) and primary HEL (human embryonic lung) cells
(Supplementary Fig. S1A and B). Thus, oncogene activation regu-
lated Apak activity and the Apak-p53 interaction dependently of
ARF.
Human ARF protein consists of 132 amino acids, among which
the N-terminal 64 residues are encoded by the unique exon 1b
[6,7]. Overexpression of the ARF N-terminal half alone is sufﬁcient
to activate p53. The N-terminal half possesses most of the known
binding abilities and has been suggested to play a pivotal role in
the tumor suppressor activity of ARF. Until recently, the C-terminal
half was shown to bind to p32 and critical for ARF to localize to
mitochondria and induce apoptosis [23]. We next determined thefunctional region of ARF required for Apak regulation. Coexpres-
sion of ARF with Apak completely blocked the repressive activity
of Apak on p53 (Fig. 2C, column 3). Overexpression of the ARF N-
terminal half (N64) alone was sufﬁcient to inhibit Apak (column
4), whereas the ARF C-terminal half (DN64) had no any effect on
Apak function (column 5). Further deletion analysis revealed that
the region comprising of aa 46–64 was required for ARF to inhibit
Apak activity (columns 6–8). Previous studies have identiﬁed ATR
to be critical for ARF-mediated activation of p53 [24]. To examine
whether ATR is involved in ARF-mediated inactivation of Apak,
endogenous ATR was depleted by RNAi and the regulatory effect
of ARF on Apak function was analyzed. Fig. 2D showed that ATR
depletion had weak effects on the ARF-mediated inactivation of
Apak, suggesting that ARF inhibited Apak activity largely indepen-
dent on ATR.
3.3. ARF interacts with Apak through the central region of aa 46-64
We next tested whether ARF inhibited Apak through direct
binding. In vitro GST pull-down assays showed that both the full-
length ARF (GST-ARF WT, lane 3) and the N-terminal ARF (GST-
ARF N64, lane 4) could strongly bind to His-tagged Apak but the
C-terminal ARF (GST-ARF DN64, lane 5) or GST alone (lane 1) could
not (Fig. 3A). As a positive control, Apak could interact with p53 as
we previously reported (lane 6) [16]. To conﬁrm the interaction be-
tween ARF and Apak in vivo, co-immunoprecipitation assays were
performed in p53-deﬁcient H1299 cells since endogenous ARF and
Apak expression is higher in such cells than the p53-wild type
cells. As shown in Fig. 3B, ARF was clearly detected in the immuno-
precipitates obtained with the anti-Apak antibody but not the pre-
immune serum. Conversely, endogenous Apak was readily
immunoprecipitated with the ARF-speciﬁc antibody which specif-
ically recognized the N-terminal part of ARF (Supplementary
Fig. S2) but not a control IgG. Importantly, even in p53-wild type
cells with low level of endogenous ARF level, ARF could be induced
by ectopic Ras-V12 expression and interactions between endoge-
nous ARF and Apak could be detected (Fig. 3C), indicating that
the ARF-Apak interaction could be induced or enhanced in re-
sponse to oncogene activation. It has been well-deﬁned that ARF
resides predominantly in the nucleolus. We previously showed
that Apak protein is localized predominantly in the nucleoplasm
and less to the nucleolus [16]. When coexpressed with exogenous
ARF, Apak was colocalized with ARF in the nucleoli (Fig. 3D). These
data indicate that ARF and Apak interact with each other both
in vitro and in vivo.
A series of ARF and Apak deletion mutants were generated and
used for mapping their interacting regions. The N-terminal ARF
comprising of aa 46–64 was required for Apak binding, whereas
either the 1–45 or 46–64 region could mediate the HDM2-binding
(Fig. 3E). The latter result is consistent with a previous study which
identiﬁed multiple regions within 1–64 of ARF-mediated MDM2
interaction and inhibition [25]. Our data indicated that the
Apak-binding and HDM2-binding regions on ARF were partially
overlapped but not conﬂicted. For Apak, the zinc-ﬁngers of Apak
mediated its interaction with ARF (Fig. 3F). Among the nine trun-
cates of Apak we examined, only the N1 (KRAB domain only)
mutant was unable to interact with ARF, suggesting that four zinc
ﬁngers are sufﬁcient for ARF binding. Since the nineteen zinc
ﬁngers of Apak are highly conserved in their sequences, the posi-
tion of the zinc ﬁngers seem to be irrelevant to the ability to bind
to ARF.
3.4. ARF competes with p53 to bind to Apak
Interestingly, we previously showed that Apak interacts with
p53 through its zinc ﬁngers. This similar pattern prompted us to
Fig. 2. ARF is required for the negative regulation of Apak by oncogenic stress. (A) H1299 cells in 24-well plate were transfected with pG13L (0.1 lg), Flag-p53 (30 ng), Myc-
Apak (0.3 lg), the oncogenes (0.2 lg), control luciferase RL-CMV (1 ng), and ARF siRNA or control siRNA (0.2 lg) as indicated. At 36 h post transfection, p53 activity was
measured by reporter gene assays. Data are mean ± S.D. (n = 3). The efﬁciency of ARF knockdown was determined by western blot. (B) H1299 cells were transfected with the
indicated plasmids and siRNAs. The cell lysates were immunoprecipitated with anti-Myc antibody to precipitate Apak proteins. The bound p53 was detected by western blot.
(C) H1299 cells were transfected with pG13L (0.2 lg), Flag-p53 (30 ng), Myc-Apak (0.4 lg), and the indicated ARF deletion mutants (0.2 lg). At 36 h post transfection, p53
activity was measured by reporter gene assays. (D) H1299 cells were transfected with pG13L (0.2 lg), RL-CMV (1 ng), Flag-p53 (30 ng), Myc-Apak (0.3 lg), ARF (0.1 lg), and
ATR siRNA or control siRNA (0.2 lg) as indicated. At 36 h post transfection, p53 activity was measured by reporter gene assays. Data are mean ± S.D. (n = 3). Apak and ARF
were analyzed by western blotting. The efﬁciency of ATR knockdown was determined by qPCR. Data are mean ± S.D. (n = 3).
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pete with p53 to bind to Apak. Apak was coexpressed with exoge-
nous p53 together gradually increased amounts of ARF. The Apak
proteins were immunoprecipitated and the bound p53 and/or
ARF proteins were detected by western blot. As shown in Fig. 4A
(lanes 1–5), the gradual increased expression of ARF signiﬁcantly
enhanced the interaction between Apak and ARF but reduced the
interaction between Apak and p53. Reciprocal experimentsshowed that p53 could also compete with ARF to bind to Apak
(lanes 6–9). The competition was dependent on the direct binding
between ARF and Apak due to the fact that ARF deleted of 46–64
residues lost the ability to compete with p53 because it could no
longer interact with Apak (lanes 10–14). Based on the fact that
endogenous ARF was elevated in response to oncogene activation,
we proposed that the elevated ARF competed with p53 to bind to
Apak, therefore disrupted the Apak-p53 interaction.
Fig. 3. Apak interacts with ARF both in vitro and in vivo. (A) Direct interaction between Apak and ARF revealed by GST pull-down assays. The wild-type GST-ARF full-length
protein, the mutants GST-ARF N64 and DN64, the positive control GST-p53, or GST alone was used in the assay with His-Apak. Both input and pull-down samples were
subjected to immunoblotting with anti-His and anti-GST antibodies. Input represents 10% of that used for pull-down. (B) Co-immunoprecipitation of endogenous Apak and
endogenous ARF from H1299 cells. Western blot analysis of whole cell lysate (WCL) and immunoprecipitation (IP) with Apak-speciﬁc antibody, ARF antibody, or control IgG.
(C) Induced interaction between Apak and ARF in response to oncogene activation. p53+/+ HCT116 cells were transfected with Ras-V12 and endogenous interaction between
Apak and ARF was detected. Both the WCL and IP samples were subjected to western blot analysis. IgG HC, heavy chain of IgG. (D) Co-localization of Apak and ARF in the
nucleoli of H1299 cells. GFP-tagged Apak and RFP-tagged ARF were co-transfected into H1299 cells. Images were captured by a confocal microscope at 36 h post transfection.
The arrows indicate ARF- and Apak-coexpressing cells. (E) (left) Mapping the region of ARF that interacts with Apak. Full-length or truncates of ARF were co-transfected with
Myc-Apak into HCT116 cells. Equal amounts of cell extract were IP with anti-Myc antibody, and analyzed by Western blot with anti-HA antibody. Both the WCL and
immunoprecipitates were analyzed. (right) Mapping the region of ARF that interacts with HDM2. Full-length or truncates of ARF were co-transfected with HDM2 into HCT116
cells. Equal amounts of cell extract were IP with anti-HDM2 antibody, and analyzed by Western blot with anti-HA antibody. Both the WCL and immunoprecipitates were
analyzed. (F) Mapping the region of Apak that interacts with ARF. Full-length or truncates of Apak and HA-ARF were transfected into HCT116 cells. Equal amounts of cell
extract were immunoprecipitated with anti-Myc antibody, and analyzed by Western blot with anti-HA antibody. Both the WCL and immunoprecipitates were analyzed. IgG
LC, light chain of IgG.
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Fig. 4. ARF competes with p53 to bind to Apak. (A) H1299 cells were transfected
with the increased amounts (1 lg, 2 lg, 4 lg) of HA-ARF (wild type or the D46–64
mutant), Flag-p53 (2 lg) and Myc-Apak (3 lg) or transfected with the increased
amounts (1, 2, 4 lg) of Flag-p53, HA-ARF (2 lg) and Myc-Apak (3 lg). Immuno-
precipitations were performed with anti-Myc antibodies; the lysates and the
immunoprecipitates were analyzed by western blot with the indicated antibodies.
(B) Apak is negatively regulated by DNA damage and oncogenic stress in the ATM-
and ARF-dependent manner, respectively.
S. Wang et al. / FEBS Letters 584 (2010) 3909–3915 3915Taken together, Apak is negatively regulated in response to DNA
damage and oncogene activation in the ATM- and ARF-dependent
manner, respectively (Fig. 4B). Based on the competitive binding
model, the balance between the abundances of ARF and p53 should
determine the switch of Apak-containing protein complex. Under
unstressed conditions, both ARF and p53 levels are kept low.
Oncogene activation induces the new synthesis of ARF, which has
been suggested to be driven by the transcription factor E2F1
[10]. Then the elevated ARF proteins overcome the low level of
p53 proteins to bind to Apak and disrupt the Apak-p53 interaction.
We also speculate that after p53 was stabilized and activated, the
p53 proteins with higher stability might contrariwise compete
with ARF to bind to Apak and are re-inhibited by Apak, preventing
the improper overactivation of p53.
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